1	Modelling population genetic screening in rare neurodegenerative diseases
2	
4 5	Thomas P Spargo MSc ^{1,*} , Alfredo Iacoangeli PhD ^{1,2,3,*,#} , Mina Ryten PhD ^{4,5,6} , Francesca Forzano MD ⁷ , Neil Pearce PhD ⁸ , and Ammar Al-Chalabi PhD ^{1,9,#} .
6 7	¹ Maurice Wohl Clinical Neuroscience Institute, King's College London, Department of Basic
8	and Clinical Neuroscience, London, UK
9 10	² Department of Biostatistics and Health Informatics, King's College London, London, UK ³ NIHR Maudsley Biomedical Research Centre (BRC) at South London and Maudsley NHS
11	Foundation Trust and King's College London, London, UK
12	Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University
13 14 15	⁵ NIHR Great Ormond Street Hospital Biomedical Research Centre, University College
15	Condon, Condon, OK ⁶ Department of Clinical Constics, Great Ormand Streat Haspital London, UK
17	⁷ Department of Clinical Genetics, Great Ormond Street Hospital, London, OK
18	⁸ Department of Medical Statistics. London School of Hygiene and Tropical Medicine. London
19	WC1E 7HT, UK.
20	⁹ King's College Hospital, Bessemer Road, London, SE5 9RS, UK.
21	
22	
23	
24	*co-first author
25	"correspondence should be addressed to <u>alfredo.iacoangeli@kcl.ac.uk</u> and <u>ammar.al-</u>
20 27	
27	Abstract
20 29	Importance: Genomic sequencing enables ranid identification of a breadth of genetic
30	variants. For clinical nurnoses, sequencing for small genetic variations is considered a solved
31	problem, while challenges remain for structural variants given the lower sensitivity and
32	specificity. Interest has recently risen among governing bodies in developing protocols for
33	population-wide genetic screening. However, usefulness is constrained when the probability
34	of being affected by a rare disease remains low despite a positive genetic test. This is a
35	common scenario in neurodegenerative disorders. The problem is recognised among
36	statisticians and statistical geneticists but less well understood by clinicians and researchers
37	who will act on these results, and by the general public who might access screening services
38	directly without the appropriate support for interpretation.
39	
40	Observations : We explore the probability of subsequent disease following genetic
41	screening of several of variants, both single nucleotide variants (SNVs) and larger repeat
42	expansions, for two neurological conditions, Huntington's disease (HD) and amyotrophic
43 44	lateral scierosis (ALS), comparing with screening for phenylketonuria which is well
44 15	established. The risk following a positive screening test was 0.5% for <i>C90rJ/2</i> in ALS and
45 46	0.470 for mance (sensitivity=99% and specificit -90%) and 12.7% for phonylkatonuric and
40 47	10.9% for ALS SOD1, when testing nathogenic SNVs (sensitivity=99.96% and
Ŧ <i>1</i>	10.5% for ALO DOD1, when results participants of vo for istraty - 55.50% and

- 48 specificity=99.95%). Subsequent screening confirmation via PCR for *C9orf72* led to a 2% risk
- 49 of developing ALS as a result of the reduced penetrance (44%).
- 50
- 51 **Conclusions and Relevance:** We show that risk following a positive screening test result
- 52 can be strikingly low for rare neurological diseases. Accordingly, to maximise the utility of
- 53 screening, it is vital to prioritise protocols of very high sensitivity and specificity, careful
- 54 selection of markers for screening, giving regard to clinical interpretability, actionability,
- 55 high penetrance, and secondary testing to confirm positive findings.
- 56
- 57
- 58 Keywords: genetic screening, genomic, next generation sequencing, health informatics,
- 59 mathematical model, Bayesian probability tools

60 Introduction

61 Single nucleotide variants (SNVs) and small insertions and deletions (indels) are now

62 genotyped in next-generation sequencing data with over 99% accuracy (1-3), while

63 genotyping larger, structural, variants is often less reliable (4). For clinical purposes, the

64 validity of sequencing for small genetic variations is considered a solved problem, while

65 challenges remain for structural variants.

66

67 Widened availability of sequencing data has favoured our understanding of the role of 68 genetic factors in various phenotypes (5-8). Genetic testing has therefore become valuable

68 genetic factors in various phenotypes (5-8). Genetic testing has therefore become valuable 69 for healthcare and gained popularity among consumers who can it directly, without advice

70 from trained clinicians to guide interpretation of results (9-11).

71

72 Interest has recently risen among governing bodies in developing protocols for population-73 wide genetic screening; such initiatives are being rolled out in the UK and considered in the 74 US (12-18). Genetic screening involves testing a population for genetic variants indicative of 75 risk for specific diseases to identify people with either higher predisposition of developing 76 that disease or the potential to pass it on to their offspring. This approach utilises modern 77 sequencing techniques to evaluate multiple genes associated with selected traits. In 78 contrast 'targeted' tests are those performed because of some suggestion that a person 79 may harbour disease variants (e.g., symptoms or family history of disease). Although 80 screening is relevant to liabilities ranging between monogenic and polygenic (cf. (16, 19)). 81 we focus here on screening for pathogenic variants with monogenic associations with rare 82 diseases, particularly as applied to neurodegenerative disorders. 83

Although no widespread implementation of genetic screening protocols currently exist internationally, comparable metabolic screening, testing neonates for metabolite markers of metabolic diseases, is routine in many countries (17, 20, 21). Positive metabolic tests are

typically validated with secondary testing, including targeted genetic tests (9, 22, 23).

88

The utility of genetic screening can be assessed by the extent to which action can be taken
following a positive test: its actionability (24, 25). One key tenet of actionability is the
probability of having or later developing a disease following a positive test. Yet post-test
disease probability can be strikingly low where disease risk prior to testing is low, as would
be for population screening for rare diseases (26).

94

95 Bayesian inference, which is routine within clinical decision making (27), can be used to 96 understand post-test ('posterior') disease risk. Under this logic, disease probability following 97 a test can be inferred given existing knowledge of the probability of other relevant events. 98 Key considerations to understanding post-test disease risk, beyond pre-test (also known as 99 'prior') disease risk, include the genetic marker penetrance, its frequency among people 100 displaying disease symptoms, and the sensitivity and specificity of the test (analytic validity). 101 This reasoning is therefore highly relevant to screening for rare neurodegenerative diseases, 102 for which genetic causes are typically rare variants of variable penetrance (28). 103 104 This article overviews important considerations for genetic screening of rare disorders and it

105 presents several case studies focused on neurodegenerative diseases. Considering

106 conditional probability in medical decision making is not novel but these concepts must be

- 107 emphasised in the genomic medicine era, since many results that could be obtained within
- 108 large-scale indiscriminate testing of genetic variation across a population will not be
- 109 actionable and may be misinterpreted. We modelled genetic screening for Huntington's
- disease (29), HD, and amyotrophic lateral sclerosis (30), ALS, using Bayesian logic to examine
- 111 the probability of disease following a positive test result for a dichotomous ALS and HD
- 112 genetic markers. We additionally modelled screening for phenylketonuria (PKU) (31), to
- 113 compare genetic and metabolic screening.
- 114

115 Methods:

116 Bayesian framework

- 117 We use Bayesian logic to calculate the probability of having or subsequently manifesting 118 disease *D* following a test result indicating presence or absence of marker *M* (the genetic
- variant). *M* is associated with increased liability of *D*, and positive test result *T* indicates
- 120 presence of *M*, while negative test result *T'* indicates its absence, denoted *M'*. Disease risk
- following a positive result is denoted P(D|T), using P(D|T') for a negative result.
- 122

Supplementary Materials 1 summarises the underlying logic. We assume that all model
 parameters represent binary events. This was a necessary simplification of reality as, for
 example, disease severity is not considered.

126

128

129

127 We estimate P(D|T) and P(D|T') using the following input parameters:

- P(D), probability of a person having or later manifesting disease D prior to testing
- P(M/D), frequency of marker M among those affected by D
- *P(D/M)*, penetrance, probability of having or later manifesting *D* for people
 harbouring *M*
- P(T/M), sensitivity (true positive rate) of the testing procedure for detecting M
- 133• P(T'|M'), specificity (true negative rate) of the testing procedure for identifying the134absence of M
- 135
 136 Bayes theorem is applied to derive the total probability of harbouring disease marker *M*,
 137 Equation 1

$$P(M) = \frac{P(D) \times P(M|D)}{P(D|M)},$$

138

and of disease *D* manifesting given the absence of *M*,

140

Equation 2

$$P(D|M') = \frac{P(D) \times \left(1 - P(M|D)\right)}{\left(1 - P(M)\right)}$$

141

142 We next calculate the total probability of positive test result *T*, *P*(*T*), according to the

sensitivity and specificity of the test and the probabilities of *M* being present versus absent:
 Equation 3

$$P(T) = P(T|M) \times P(M) + (1 - P(T'|M')) \times (1 - P(M)).$$

145

146 Bayes theorem is then used to derive the probabilities of *M* being present after positive,

147

 $P(M|T) = \frac{P(M) \times P(T|M)}{P(T)} ,$

148

149 and negative,

150

 $P(M|T') = \frac{P(M) \times (1 - P(T|M))}{(1 - P(T))},$

151 results.

152

153 The probabilities of manifesting disease *D* (which has conditional independence from *T*

154 when considering *M*) after receiving positive test result *T*, 155

$$P(D|T) = P(D|M) \times P(M|T) + P(D|M') \times (1 - P(M|T)),$$

156157 and negative test result T',

158

 $P(D|T') = P(D|M) \times P(M|T') + P(D|M') \times (1 - P(M|T')),$

159

160 can then be determined.

161 162 Case studies

163 The Project MinE (32), ALS variant server (33), ClinVar (34), and gnomAD databases were 164 searched alongside the previous databases and next-generation sequencing tool 165 benchmarking reports to obtain data for the included case studies. Most input parameters 166 were defined using data from published literature and online databases. Sensitivity (P(T|M))and specificity (P(T|M)) were defined by performance benchmarks for variant calling with 167 168 state-of-the-art genomic sequencing techniques specialised for genotyping particular 169 variant types (see Supplementary Materials 2; Table S1). Although analytical accuracy will 170 vary across the genome and other sources of error exist, these heuristics are sufficient for 171 our purposes.

172

Table 1 presents the parameter estimates and post-test disease risks calculated across
various scenarios. A comprehensive description of parameter ascertainment, including
penetrance estimation, is given in Supplementary Materials 3; Table S2 summarises the
assumptions and corresponding reality.

177 178

179 Case 1 – Huntington's disease

180 HD is a late-onset Mendelian disease with autosomal dominant inheritance caused by a

181 trinucleotide, CAG, short tandem repeat expansion (STRE) in the *HTT* gene (OMIM:

- 182 613004). We let *M* be a CAG expansion of >40 repeat units, which would have complete
- 183 penetrance in a normal lifespan (29).

184

Equation 6

Equation 4

Equation 5

Equation 7

We modelled two scenarios for this example, (1) as in genetic screening, defining pre-test disease probability by baseline risk of HD in a general population and (2) as a targeted test, considering pre-test disease probability for an individual whose parent harbours the fully penetrant *HTT* STRE and who has a 0.5 probability of inheriting *M* (we have not modelled genetic anticipation (35)).

190

191 *Case 2 – amyotrophic lateral sclerosis*

ALS is a late-onset disease with locus and allelic heterogeneity; genetic associations with risk and phenotype modification range between monogenic and polygenic. Variants in at least 40 genes are associated with ALS (30, 36-38). *SOD1* (OMIM: 147450) and *C9orf72* (OMIM: 614260) are the most frequently implicated genes, where variants of each account for fewer than 10% of cases. Autosomal dominant inheritance is typical for most people with a known genetic disease cause.

198

199 We modelled several definitions of markers for ALS risk, drawing from three of the 200 commonest ALS genes: SOD1, C9orf72, and FUS (OMIM: 137070). SOD1- and FUS-linked ALS 201 is typically attributed to SNVs and many pathogenic variants with varying strength of 202 supporting evidence have been reported in these genes (39). The pathogenic form of 203 *C9orf72* is a hexanucleotide, GGGGCC, STRE associated principally with the onset of either 204 one or both of ALS and frontotemporal dementia (40). Known variants in these genes have 205 typically incomplete penetrance; examples include ~90-100% penetrance for SOD1 p.A5V 206 and ~45% for the C9orf72 STRE (41, 42).

207

208 The definitions of *M* modelled in this case study were:

- SOD1 (all) M includes any rare variant reported in people with ALS of European ancestry contained within the meta-analysis sample set from which the variant frequencies were derived (see Supplementary Materials 3.2) (37).
- SOD1 (A5V) M represents the pathogenic SOD1 p.A5V variant, one of the most
 common SOD1 variants among North American ALS populations, characterised by
 high penetrance (41, 43).
- *FUS* (all) *M* includes any rare variant reported in people with ALS of European ancestry contained within the meta-analysis sample set from which the variant frequencies were derived (see Supplementary Materials 3.2) (37).
- *FUS* (ClinVar) *M* includes any of 21 *FUS* variants reported as pathogenic or likely
 pathogenic for ALS within ClinVar and present within databases of familial and
 sporadic ALS (see Table S3) (32-34).
- 221 222

• C9orf72 – M represents a pathogenic C9orf72 STRE of 30≤ repeat GGGGCC units within the first intron of the C9orf72 gene.

In the SOD1 (all) and FUS (all) scenarios, M encompasses variants classed as pathogenic,
likely pathogenic, and variants of uncertain significance (44). It is appropriate to model
these scenarios since many variants of uncertain significance in ALS-implicated genes have a
high probability of being deleterious and should not necessarily be ignored (38).

226 227

For the *C9orf72* marker, we modelled two scenarios: (1) genetic screening with sensitivity and specificity defined by performance of existing tools for genotyping STREs in sequencing data; (2) using repeat-primed polymerase chain reaction with amplicon-length analysis (45)

as a secondary test to validate a positive result from screening via sequencing in scenario 1.

232

233 Case 3 – phenylketonuria

234 PKU is an autosomal recessive disease with infantile onset, caused by variants in the PAH

235 gene (OMIM: 612349) (31); most variants pathogenic for PKU are SNVs. *M* represents being

236 homozygous or compound heterozygous for any of the three most common *PAH* variants

recorded in European populations of people with PKU: p.Arg408Trp, c.1066-11G>A,

238 p.Arg261Gln (31).

239

240 We modelled two testing scenarios for PKU: (1) genetic screening, with pre-test disease

probability defined per the baseline population risk of PKU, and (2) secondary testing to

confirm positive results obtained using tandem mass spectrometry (46) as in established

243 metabolic screening protocols (see Supplementary Materials 3.3).

Table 1. Input parameters and disease risk estimates following testing for all case study scenarios.

Parameter ascertainment is comprehensively described within Supplementary Materials 3. HD = Huntington's disease; ALS = amyotrophic lateral sclerosis; PKU = phenylketonuria. SNV = single nucleotide variant; STRE = short tandem repeat expansion. [§]Estimates are based on populations of predominantly European ancestry – 95% confidence intervals shown for newly derived estimates in the ALS case study; ^{*}includes FUS variants classified as pathogenic or likely pathogenic for ALS in the ClinVar database and recorded within ALS population databases (see Table S3, Table S4); ¹defined by variant calling performance benchmarks of tools for genotyping in sequencing data by variant type (see Table S1) and, where marked [†], by aggregate laboratory accuracy for genotyping C9 or f72 STRE with repeat-primed polymerase chain reaction and amplicon-length analysis (45). ^ΩRisk following positive results in primary screening and confirmatory

Case study	Gene containing marker (case study scenario)	Variant type	Pre-test disease probability [§]	Marker frequency in people affected [§]	Penetrance [§]	Test sensitivity [¶]	Test specificity ¶	Disease risk after positive test	Disease risk after negative test	Relative disease risk after positive rather than negative test
-	-	-	P(D)	P(M D)	P(D M)	P(T M)	P(T' M')	P(D T)	P(D T')	-
1: HD	HTT (screening)	STRE	0.000410	1.000	1.000	0.990	0.900	0.00404	0.00000456	887
	HTT (targeted)	STRE	0.500	1.000	1.000	0.990	0.900	0.908	0.011	82.7
2: ALS 3: PKU	<i>SOD1</i> (all)	SNV	0.00333	0.0188 (0.0138, 0.0238)	0.701 (0.491, 0.926)	0.9996	0.9995	0.109	0.00327	33.3
	<i>SOD1</i> (A5V)	SNV	0.00333	0.000529 (4.43x10 ⁵ , 0.00101)	0.91	0.9996	0.9995	0.00683	0.00333	2.05
	<i>FUS</i> (all)	SNV	0.00333	0.00425 (0.0023, 0.0062)	0.579 (0.291 <i>,</i> 0.884)	0.9996	0.9995	0.0302	0.00332	9.09
	FUS (ClinVar*)	SNV	0.00333	0.00251 (0.00125, 0.00377)	0.536 (0.211, 0.877)	0.9996	0.9995	0.0194	0.00333	5.84
	C9orf72	STRE	0.00333	0.0635 (0.0538 <i>,</i> 0.0732)	0.439 (0.358, 0.520)	0.990	0.900	0.00519	0.00313	1.66
	C9orf72 (positive sequencing screening confirmation)	STRE	0.0052	0.0635 (0.0538, 0.0732)	0.439 (0.358, 0.520)	0.95 [†]	0.98 [†]	0.0198	0.00489	4.06 (6.35 ^Ω)
	PAH (screening)	SNV	0.000100	0.743	0.892	0.9996	0.9995	0.127	0.0000257	4,961
	PAH (positive metabolic screening confirmation)	SNV	0.167	0.743	0.892	0.9996	0.9995	0.889	0.0497	17.9 (889,000 ^Ω)

tests relative to a negative screening result (probability of PKU given a negative metabolic screening result is approximated as 1×10°).

244 **Results and Discussion**

245

246 **Post-test disease probability**

247 Screening versus diagnostic testing

Across case studies, we showed low probability of disease following positive results within

249 contextually-blind genetic screening scenarios; risk ranged between 12.7% and 0.4% (see

250 Table 1). Disease risk was always negligible following a negative test result, indicating

absence of the tested variant, as would be seen for any rare trait.

252

The HD case study illustrates the distinction between contextually-blind screening and diagnostic testing for rare diseases: following a positive test result, lifetime HD risk was high (90.8%) using targeted testing but low (0.4%) in screening. This difference reflects that,

256 unlike screening, targeted testing is performed based on some indication of a person's

elevated disease risk (e.g., existing disease symptoms or family history). Accordingly, pre-

test disease probability is greater. Inherently low pre-test disease probability will be a

- 259 pervasive issue in screening for rare diseases.
- 260

261 Relative risk and secondary testing

The utility of a test for identifying at-risk individuals can be examined based on relative disease risk following positive rather than negative test results: utility is limited when risk is only minimally greater for people testing positive rather than negative. This is observed in the ALS *C9orf72* case study, where risk was only 1.7 times greater (Table 1) following a positive screening from sequencing alone, despite this variant being the most common

- 267 genetic cause of ALS (37).
- 268

We additionally observed 6.35 times greater ALS risk for a person testing positive on both screening for *C9orf72* and a secondary test than for a person testing negative on the initial screening. This increased relative risk reflects that a person testing positive on two independent measures of disease risk has greater absolute probability of disease than after

- the initial screening result alone.
- 274

We emphasise that secondary testing is important to increase certainty in positive tests. The PKU case study demonstrates its potentially sizable impact. A positive screening result using the established metabolic approach alone indicated 16.7% PKU risk, versus 12.7% within genetic screening. The metabolic marker, which is universal across people with PKU and

indicates existing disease manifestation, eclipses need for genetic screening for PKU,

280 marked by variants with incomplete penetrance that are not present for all people with

281 PKU. However, the genetic test remains useful for validating the positive metabolic

screening result (17): probability of PKU following a confirmatory genetic test conducted on
 the basis of a positive metabolic screening result was 88.9%.

284

The overall benefit of secondary testing will however differ by scenario. For ALS, the risk

- remained moderate (~2%) despite two positive test results for *C9orf72*.
- 287

288 Constraints upon post-test disease probability

Figure 1, Figure 2, and Figure 3 illustrate how the post-test disease probability reduces as

290 the probability of any test, disease, or marker characteristic decreases. Sensitivity and

291 specificity critically constrain certainty about post-test disease risk, and this role is amplified 292 as the other parameter probabilities decrease. Figure 1 particularly demonstrates the 293 increased role of specificity in rarer diseases, where disease risk following a positive test

294 result will be moderated only by penetrance in a protocol of perfect specificity.



296 297

295

298 Figure 1. Probability of a disease given a positive genetic test result for a marker of increased disease risk (P(D|T)) according 299 to the sensitivity (P(T|M)) and the specificity (P(T'|M')) of the testing protocol

300 Panel A presents this for a disease with pre-test probability (P(D)) of 0.5, while panel B presents a disease with P(D) of 0.01. 301 Penetrance is complete (P(D|M) = 1) and variant M is harboured by all people with disease D(P(M|D) = 1) in both panels.





- 302 303 Figure 2. Probability of disease D following a positive genetic test result for marker M (P(D|T)) according to pre-test disease 304 probability (P(D))
- 305 *M* occurs in all people with D(P(M|D) = 1) and has complete penetrance (P(D|M) = 1)). Plot lines are defined according to
- 306 sensitivity (P(T|M)) and specificity (P(T'|M')) of existing protocols for genotyping variant types (see Supplementary
- 307 Materials 2): single nucleotide variant (SNV), P(T|M) = 0.9996, P(T'|M') = 0.9995; small insertion or deletion (Indel), P(T|M)
- 308 = 0.9962, P(T'|M') = 0.9971; short tandem repeat expansion (STRE), P(T|M)=0.99, P(T'|M') = 0.90; copy number variant
- 309 (CNV) - del. (deletion), P(T|M) = 0.289, P(T'|M') = 0.959; CNV - dup. (duplication), P(T|M) = 0.1020, P(T'|M') = 0.9233.



310P(M|D) = 1, P(T|M) = 0.9996, P(T'|M') = 0.9995P(M|D) = 1, P(T|M) = 0.99, P(T'|M') = 0.90311Figure 3. Change in disease risk following a positive test result for a marker of increased disease risk (P(D|T)) according to312penetrance (P(D|M))

Panels A and B display modelled and hypothetical markers of ALS which differ in frequency across people affected by ALS
 (P(M|D)), where pre-test disease probability (P(D)) is 0.0033 and diamonds mark the penetrance estimated for non-

³¹⁵ hypothetical variants (see Table 1). Panels C and D display diseases in which P(M|D) = 1 and with P(D) set in line with the

³¹⁶ modelled case studies or a hypothetical rare disease. Analytic validity parameters are defined according to the performance

³¹⁷ of sequencing tools for genotyping single nucleotide variants in A and C, and of short tandem repeat expansions in B and D

³¹⁸ (see Table S1; Figure 2).

- As is well-recognised, high sensitivity and specificity are essential to maximise utility of
- 321 testing. The respective trade-offs between prioritising each of these must be regarded: high
- 322 sensitivity is required to detect markers, while high specificity increases confidence in
- positive results. Established screening protocols prioritise high sensitivity to maximise
- detection of at-risk individuals, with confirmatory secondary testing being vital to minimise
- 325 false-positive results (9, 22, 23).
- 326
- Since the characteristics of diseases and associated variants are all pre-determined within a population, disease markers (variants) screened should be chosen carefully. The most useful variants will be those more prevalent among people affected, of high penetrance, and which can be genotyped with high sensitivity and specificity (see Table 1, ALS case study;
- 331 Figure 3, panels A and B).
- 332

333 Practical implementation of genetic screening

- 334 Marker selection
- Before a marker is used in screening, its relevance across people must be evaluated,
- recognising that this may vary by ancestry. For instance, particular variants may be less
- 337 common or only present in certain populations, and penetrance can also vary between
- them (36, 43). Screening protocols must therefore account for these differences to prevent
- 339 systemic inequalities, especially for minorities which are often under-studied and therefore
- 340 have limited genetic information available.
- 341
- Regard must be given to the clinical interpretability of selected markers. We illustrated
- several approaches to defining markers in the ALS case study. Within the SOD1 (all)
- scenario, disease risk is marked by an aggregation of putatively pathogenic *SOD1* variants.
- 345 Without curation, the relationship to disease varies across them. E.g., SOD1 p.I114T has
- 346 substantially lower penetrance than p.A5V, and many potentially relevant variants have
- 347 uncertain significance (34, 38, 39, 42). Curation could involve defining a positive result as
- 348 presence of variants with sufficient evidence of pathogenicity (44), as in the FUS (ClinVar)
- 349 scenario, or as harbouring specific variants, as in the SOD1 (A5V) scenario.
- 350

De novo variants and variants of uncertain significance present a substantial challenge for
 screening since they will frequently be identified, yet must be set aside until variant
 interpretation is possible despite potentially being deleterious (12). PKU demonstrates the
 scale of this issue for rare diseases with multiple implicated variants, as 55% of deleterious

- 355 *PAH* genotypes are observed uniquely (31).
- 356

357 Utility over time and actionability

358 As genetic screening is possible from birth, while non-genetic methods may not be, age of 359 viability for screening methods should be evaluated. For late-onset diseases, early genetic 360 screening may enable preventative treatments to at-risk individuals or close monitoring for 361 prodromal disease markers. For instance, rapid eye movement sleep behaviour disorder is a 362 prodromal feature for Parkinson's disease (47) and monitoring of at-risk individuals may 363 enable early intervention. The influence of time upon treatment viability and effectiveness 364 must also be considered. For example, genetic therapy has potential utility for preventing or 365 delaying onset of degenerative disorders (48).

366

- 367 The ultimate benefit of early identification of disease risk through genetic screening is
- 368 contingent upon the actionability of the result. A framework of actionability (24, 25), shown
- to align with laypersons' views on treatment acceptability (49), states that actionability is
- determined by: disease likelihood and severity, intervention effectiveness in disease
- 371 minimisation or prevention, and the consequence of the intervention to a person and risk if
- 372 not performed. Each of these elements are critical when selecting traits and markers for
- 373 genetic screening and for the clinical interpretation of results.
- 374

375 Limitations

- The Bayesian logic in the case studies simplifies genotype-phenotype relationships and
 cannot address all considerations relevant to clinical genetic testing. Phenotype variability is
 not considered. Other factors include: polygenicity and oligogenicity, pleiotropy, the role of
- 379 genetic and environmental modifying factors, and that of additive genetic effects in
- 380 recessive conditions and heterozygous carriers of pathogenic variants. Such influences can
- fundamentally impact both the probability that a disease will manifest and its severity. For
- instance, although spinal muscular atrophy is caused by partial or complete biallelic deletion
- 383 of the SMN1 gene, additional copies of SMN2 reduce disease expressivity by mitigating loss
- of *SMN1* function (50). Any results from genetic screening must be interpreted within the
- 385 wider context of that disease and its modifiers.
- 386

387 Conclusion

We have shown that risk following a positive screening test result can be strikingly low for rare neurological diseases. Accordingly, to maximise the utility of screening, we suggest prioritising protocols of very high sensitivity and specificity, careful selection of markers for screening, giving regard to clinical interpretability, and secondary testing to confirm positive findings.

393

A key advantage of a genetic screening approach for late-onset diseases is that these
 markers can be examined across the lifespan. Hence, positive test results could be useful for
 targeting people for prevention, and for monitoring of prodromal features.

396 397

398 Although considering disease risk within a Bayesian context is not novel, it is important to 399 stress the considerations raised here at a time when governments evaluate implementation 400 of genomic sequencing for population screening and as access to genetic testing outside 401 healthcare settings increases. While genetic screening has many potential benefits, the 402 limitations of such an approach should be properly understood. Policy makers must 403 consider the impact of a positive test result on large numbers of people that will never 404 develop a given disease, a particularly salient issue for late-onset diseases. Although not the 405 present focus, the substantial ethical and social considerations raised in conjunction to 406 screening must also be regarded (13).

- 407
- 408

409 Data Availability

- 410 Data sharing not applicable
- 411
- 412

413 Acknowledgements

414 We wish to thank Professor Naomi Wray of the Queensland Brain Institute for her

415 contribution to project conceptualisation and methodology. We also thank Dr Leslie

416 Biesecker of the National Human Genome Research Institute of the National Institutes of

417 Health for contributing to our discussions around this work.

418

419 **Author contributions**

- 420 **TPS**: Conceptualisation, Methodology, Formal analysis, Investigation, Data Curation, Writing
- 421 Original Draft, Writing Review and Editing, Visualisation. AI: Conceptualisation,
- 422 Methodology, Writing Original Draft, Writing Review and Editing, Supervision. MR:
- 423 Conceptualisation, Writing Review and Editing. FF: Conceptualisation, Writing Review
- 424 and Editing. NP: Conceptualisation, Writing Review and Editing. AAC: Conceptualisation,
- 425 Methodology, Writing Review and Editing, Supervision.
- 426

427 Funding

428 AAC is an NIHR Senior Investigator. This is an EU Joint Programme-Neurodegenerative

- 429 Disease Research (JPND) project. The project is supported through the following funding
- 430 organizations under the aegis of JPND (United Kingdom, Medical Research Council
- 431 MR/L501529/1 and MR/R024804/1; Economic and Social Research Council ES/L008238/1)
- and through the Motor Neurone Disease Association. This study represents independent
- 433 research part funded by the NIHR Maudsley Biomedical Research Centre at South London
- 434 and Maudsley NHS Foundation Trust and King's College London. The work leading up to this
- 435 publication was funded by the European Community's Horizon 2020 Programme (H2020-
- 436 PHC-2014-two-stage; grant 633413). This work was part funded by my Name'5 Doddie
- 437 Foundation, and Alan Davidson Foundation. The views expressed are those of the author(s)
- and not necessarily those of the NHS, the NIHR, King's College London, or the Department
- 439 of Health and Social Care. AI is funded by South London and Maudsley NHS Foundation
- 440 Trust, MND Scotland, Motor Neurone Disease Association, National Institute for Health and
- 441 Care Research, Spastic Paraplegia Foundation, Rosetrees Trust, Darby Rimmer MND
- 442 Foundation, the Medical Research Council (UKRI) and Alzheimer's Research UK.
- 443

444 Role of the funding source

The funding sources had no role in the writing of this manuscript or the decision to submit itfor publication.

447

448 **Declaration of interests**

449 AI, MR, FF, and NP declare no competing interests. TPS declares employment with

- 450 AstraZeneca. AAC declares royalties from The Brain, A Beginner's Guide: Oneworld
- 451 Publications, and The Genetics of Complex Human Diseases, A Laboratory Manual. AAC
- 452 reports consultancies or advisory boards for Amylyx, Apellis, Biogen, Brainstorm,
- 453 Cytokinetics, GenieUs, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma,
- 454 Quralis, Sano, Sanofi, and Wave Pharmaceuticals. AAC is the deputy editor for Brain. AAC
- 455 has planned patents for 'Use of CSF-Neurofilament determinations and CSF-Neurofilament
- 456 thresholds of prognostic and stratification value with regards to response to therapy in
- 457 neuromuscular and neurodegenerative diseases'. AAC is Scientific co-lead for United to End
- 458 MND Partnership Coalition and Guarantor of Brain. AAC has stock options for Quralis.

459	
460	
461	

462 463 **References:** 464 1. Iacoangeli A, Al Khleifat A, Sproviero W, Shatunov A, Jones AR, Morgan SL, et al. 465 DNAscan: personal computer compatible NGS analysis, annotation and visualisation. BMC 466 Bioinform. 2019;20(1):213. 467 Wenger AM, Peluso P, Rowell WJ, Chang P-C, Hall RJ, Concepcion GT, et al. Accurate 2. 468 circular consensus long-read sequencing improves variant detection and assembly of a 469 human genome. Nat Biotechnol. 2019;37(10):1155-62. 470 Illumina. Accuracy Improvements in Germline Small Variant Calling with the DRAGEN 3. 471 Platform2019 07/09/2019. Available from: https://science-472 docs.illumina.com/documents/Informatics/dragen-v3-accuracy-appnote-html-970-2019-006/Content/Source/Informatics/Dragen/dragen-v3-accuracy-appnote-970-2019-473 474 006/dragen-v3-accuracy-appnote-970-2019-006.html. 475 Kosugi S, Momozawa Y, Liu X, Terao C, Kubo M, Kamatani Y. Comprehensive 4. 476 evaluation of structural variation detection algorithms for whole genome sequencing. 477 Genome Biol. 2019;20(1):117. 478 5. Rhoades R, Jackson F, Teng S. Discovery of rare variants implicated in schizophrenia 479 using next-generation sequencing. J transl genet genom. 2019;3:1. 480 6. Davey JW, Hohenlohe PA, Etter PD, Boone JQ, Catchen JM, Blaxter ML. Genome-481 wide genetic marker discovery and genotyping using next-generation sequencing. Nat Rev 482 Genet. 2011;12(7):499-510. 483 7. Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, et al. Gene discovery and 484 polygenic prediction from a genome-wide association study of educational attainment in 1.1 485 million individuals. Nat Genet. 2018;50(8):1112-21. 486 8. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank 487 resource with deep phenotyping and genomic data. Nature. 2018;562(7726):203-9. 488 9. Hörster F, Kölker S, Loeber JG, Cornel MC, Hoffmann GF, Burgard P. Newborn 489 Screening Programmes in Europe, Arguments and Efforts Regarding Harmonisation: Focus 490 on Organic Acidurias. JIMD Rep. 2017;32:105-15. 491 Perrone F, Cacace R, Van Mossevelde S, Van den Bossche T, De Deyn PP, Cras P, et al. 10. 492 Genetic screening in early-onset dementia patients with unclear phenotype: relevance for 493 clinical diagnosis. Neurobiol Aging. 2018;69:292.e7-.e14. 494 11. Majumder MA, Guerrini CJ, McGuire AL. Direct-to-Consumer Genetic Testing: Value 495 and Risk. Annu Rev Med. 2021;72(1):151-66. 496 12. Murray MF, Evans JP, Khoury MJ. DNA-Based Population Screening: Potential 497 Suitability and Important Knowledge Gaps. JAMA. 2019. 498 13. Dickinson JA, Pimlott N, Grad R, Singh H, Szafran O, Wilson BJ, et al. Screening: when 499 things go wrong. Can Fam Physician. 2018;64(7):502-8. 500 14. Jansen ME, Lister KJ, van Kranen HJ, Cornel MC. Policy Making in Newborn Screening 501 Needs a Structured and Transparent Approach. Front Public Health. 2017;5(53). 502 15. Genome UK: The future of healthcare. 503 https://www.gov.uk/government/publications/genome-uk-the-future-of-healthcare 2020. 504 16. Moorthie S, Hall A, Janus J, Brigden T, Villiers CBd, Blackburn L, et al. Polygenic scores 505 and clinical utility. University of Cambridge; 2021. 506 17. Adhikari AN, Gallagher RC, Wang Y, Currier RJ, Amatuni G, Bassaganyas L, et al. The 507 role of exome sequencing in newborn screening for inborn errors of metabolism. Nat Med. 508 2020;26(9):1392-7.

509 Centers for Disease Control and Prevention. Use of Genomics in Newborn Screening 18. 510 Programs: The Promise and Challenges 2021 [Available from: 511 https://www.cdc.gov/genomics/events/newborn screening 2021.htm. 512 Pain O, Gillett AC, Austin JC, Folkersen L, Lewis CM. A tool for translating polygenic 19. 513 scores onto the absolute scale using summary statistics. Eur J Hum Genet. 2022;30:339-48. 514 Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, et al. Newborn 20. 515 screening programmes in Europe; arguments and efforts regarding harmonization. Part 1 -516 From blood spot to screening result. J Inherit Metab Dis. 2012;35(4):603-11. 517 21. Tarini BA, Christakis DA, Welch HG. State Newborn Screening in the Tandem Mass 518 Spectrometry Era: More Tests, More False-Positive Results. Pediatrics. 2006;118(2):448. 519 22. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, et al. A 520 survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros. 2007;6(1):57-65. 521 23. Rinaldo P, Zafari S, Tortorelli S, Matern D. Making the case for objective performance 522 metrics in newborn screening by tandem mass spectrometry. Ment Retard Dev Disabil Res 523 Rev. 2006;12(4):255-61. 524 Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, et al. ClinGen 24. 525 - The Clinical Genome Resource. N Engl J Med. 2015;372(23):2235-42. 526 Hunter JE, Irving SA, Biesecker LG, Buchanan A, Jensen B, Lee K, et al. A standardized, 25. 527 evidence-based protocol to assess clinical actionability of genetic disorders associated with 528 genomic variation. Genet Med. 2016;18(12):1258-68. 529 26. Biesecker LG. Genomic screening and genomic diagnostic testing-two very different 530 kettles of fish. Genome Med. 2019;11(1):75. 531 27. Hunink MGM, Weinstein MC, Wittenberg E, Drummond MF, Pliskin JS, Wong JB, et 532 al. Decision Making in Health and Medicine: Integrating Evidence and Values. 2nd ed. 533 Cambridge: Cambridge University Press; 2014. 534 28. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin 535 Invest. 2005;115(6):1449-57. 536 29. Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for 537 prediction of the age of onset and penetrance for Huntington's disease based on CAG 538 length. Clin Genet. 2004;65(4):267-77. 539 30. Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N Engl J Med. 540 2017;377(2):162-72. 541 31. Hillert A, Anikster Y, Belanger-Quintana A, Burlina A, Burton BK, Carducci C, et al. The 542 Genetic Landscape and Epidemiology of Phenylketonuria. Am J Hum Genet. 543 2020;107(2):234-50. 544 32. van der Spek RAA, van Rheenen W, Pulit SL, Kenna KP, van den Berg LH, Veldink JH. 545 The project MinE databrowser: bringing large-scale whole-genome sequencing in ALS to 546 researchers and the public. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:432-547 40. 548 33. ALS Variant Server [Internet]. [cited 02/2021]. Available from: 549 http://als.umassmed.edu/. 550 34. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: 551 improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 552 2018;46(D1):D1062-D7. 553 35. Paulson H. Repeat expansion diseases. Handb Clin Neurol. 2018;147:105-23.

554 36. lacoangeli A, Al Khleifat A, Sproviero W, Shatunov A, Jones AR, Opie-Martin S, et al. 555 ALSgeneScanner: a pipeline for the analysis and interpretation of DNA sequencing data of 556 ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:207-15. 557 37. Zou Z-Y, Zhou Z-R, Che C-H, Liu C-Y, He R-L, Huang H-P. Genetic epidemiology of 558 amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg 559 Psychiatry. 2017;88:540-9. 560 38. Mehta PR, Iacoangeli A, Opie-Martin S, van Vugt J, Al Khleifat A, Bredin A, et al. The 561 impact of age on genetic testing decisions in amyotrophic lateral sclerosis. Brain. 562 2022;145(12):4440-7. 563 Abel O, Powell JF, Andersen PM, Al-Chalabi A. ALSoD: A user-friendly online 39. 564 bioinformatics tool for amyotrophic lateral sclerosis genetics. Hum Mutat. 2012;33(9):1345-565 51. 566 40. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, et al. A 567 hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-568 FTD. Neuron. 2011;72(2):257-68. 569 41. Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, et al. 570 Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Annals 571 of Neurology. 1997;41(2):210-21. 572 42. Spargo TP, Opie-Martin S, Bowles H, Lewis CM, Iacoangeli A, Al-Chalabi A. Calculating 573 variant penetrance from family history of disease and average family size in population-574 scale data. Genome Med. 2022;14:141. 575 Saeed M, Yang Y, Deng HX, Hung WY, Siddique N, Dellefave L, et al. Age and founder 43. 576 effect of SOD1 A4V mutation causing ALS. Neurology. 2009;72(19):1634-9. 577 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and 44. 578 guidelines for the interpretation of sequence variants: a joint consensus recommendation of 579 the American College of Medical Genetics and Genomics and the Association for Molecular 580 Pathology. Genet Med. 2015;17(5):405-23. 581 Akimoto C, Volk AE, van Blitterswijk M, Van den Broeck M, Leblond CS, Lumbroso S, 45. 582 et al. A blinded international study on the reliability of genetic testing for GGGGCC-repeat 583 expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med 584 Genet. 2014;51(6):419. 585 Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF. 46. 586 Expanded newborn screening for inborn errors of metabolism by electrospray ionization-587 tandem mass spectrometry: results, outcome, and implications. Pediatrics. 588 2003;111(6):1399-406. 589 47. Ferini-Strambi L, Marelli S, Galbiati A, Rinaldi F, Giora E. REM Sleep Behavior Disorder 590 (RBD) as a marker of neurodegenerative disorders. Arch Ital Biol. 2014;152(2-3):129-46. 591 Amado DA, Davidson BL. Gene therapy for ALS: A review. Mol Ther. 48. 592 2021;29(12):3345-58. 593 49. Paguin RS, Mittendorf KF, Lewis MA, Hunter JE, Lee K, Berg JS, et al. Expert and lay 594 perspectives on burden, risk, tolerability, and acceptability of clinical interventions for 595 genetic disorders. Genet Med. 2019;21(11):2561-8. 596 Wadman RI, Jansen MD, Stam M, Wijngaarde CA, Curial CAD, Medic J, et al. 50. 597 Intragenic and structural variation of the SMN locus and clinical variability of spinal muscular 598 atrophy. Brain Commun. 2020;2(2):fcaa075. 599